- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eyepoint Pharmaceuticals Inc (EYPT)
Eyepoint Pharmaceuticals Inc stock price live, this page displays NASDAQ EYPT stock exchange data. View the EYPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eyepoint Pharmaceuticals Inc real time stock price chart below.
What Is the Eyepoint Pharmaceuticals Inc Stock Price Today?
The Eyepoint Pharmaceuticals Inc stock price today is 16.125.
What Is the Stock Symbol for Eyepoint Pharmaceuticals Inc?
The stock symbol for Eyepoint Pharmaceuticals Inc is "EYPT."
What Stock Exchange Does Eyepoint Pharmaceuticals Inc Trade On?
Eyepoint Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eyepoint Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
What Is the Eyepoint Pharmaceuticals Inc Stock Price Today?
The Eyepoint Pharmaceuticals Inc stock price today is 16.125.
What Is the Stock Symbol for Eyepoint Pharmaceuticals Inc?
The stock symbol for Eyepoint Pharmaceuticals Inc is "EYPT."
What Stock Exchange Does Eyepoint Pharmaceuticals Inc Trade On?
Eyepoint Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eyepoint Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eyepoint Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EYPT quote. (ISIN: US30233G2093)
16.125
+0.595(+3.83%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.600
16.325
52 wk Range
3.910
19.110
EYPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.60016.325
52 wk Range
3.91019.110
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EYPT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
36.083
Upside
+123.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Eyepoint Pharmaceuticals Inc Company Profile
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- EyePoint Pharmaceuticals reported Q3 2025 revenue of $966,000, missing expectations by 72.08%, with EPS of -0.85 falling short of the -0.77 forecast, causing shares to drop 7.26% in premarket trading.
- Operating expenses increased to $63 million (up from $43.3 million YoY) while revenue declined from $10.5 million in Q3 2024, resulting in a net loss of $59.7 million for the quarter.
- Despite financial challenges, the company maintains a strong cash position of $204 million, expected to fund operations into Q4 2027 as it advances its lead product Duraview.
- Management remains optimistic about Duraview's potential in wet AMD and DME markets, with top-line AMD data expected by mid-2026 and first DME trial dosing in Q1 2026.
- CEO Dr. Jay Duker highlighted the company's leadership in sustained-release therapies, noting that approximately 65% of patients did not require supplemental anti-VEGF injections during trials.
Last Updated: 2025-11-05, 09:34 a/m
Read Full TranscriptCompare EYPT to Peers and Sector
Metrics to compare | EYPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEYPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.5x | −5.4x | −0.6x | |
PEG Ratio | 0.13 | 0.22 | 0.00 | |
Price/Book | 6.7x | 1.4x | 2.6x | |
Price / LTM Sales | 31.6x | 2.6x | 3.4x | |
Upside (Analyst Target) | 112.5% | 17.1% | 42.5% | |
Fair Value Upside | Unlock | 20.2% | 5.8% | Unlock |
Analyst Ratings
13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 36.083
(+123.77% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-0.85 / -0.77
Revenue / Forecast
966.00K / 3.46M
People Also Watch
FAQ
What Is the Eyepoint Pharma (EYPT) Stock Price Today?
The Eyepoint Pharma stock price today is 16.125
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is "EYPT."
What Is the Eyepoint Pharma Market Cap?
As of today, Eyepoint Pharma market cap is 1.34B.
What Is Eyepoint Pharma's Earnings Per Share (TTM)?
The Eyepoint Pharma EPS (TTM) is -3.00.
When Is the Next Eyepoint Pharma Earnings Date?
Eyepoint Pharma will release its next earnings report on Mar 05, 2026.
From a Technical Analysis Perspective, Is EYPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Eyepoint Pharma Stock Split?
Eyepoint Pharma has split 2 times.
How Many Employees Does Eyepoint Pharma Have?
Eyepoint Pharma has 165 employees.
What is the current trading status of Eyepoint Pharma (EYPT)?
As of Jan 22, 2026, Eyepoint Pharma (EYPT) is trading at a price of 16.125, with a previous close of 15.530. The stock has fluctuated within a day range of 15.600 to 16.325, while its 52-week range spans from 3.910 to 19.110.
What Is Eyepoint Pharma (EYPT) Price Target According to Analysts?
The average 12-month price target for Eyepoint Pharma is USD36.083, with a high estimate of USD68 and a low estimate of USD20. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +123.77% Upside potential.
What Is the EYPT Premarket Price?
EYPT's last pre-market stock price is 15.500. The pre-market share volume is 1,900.000, and the stock has decreased by -0.030, or -0.190%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.